Host intestinal epithelial surface glycoconjugates

Host intestinal epithelial surface glycoconjugates are complex carbohydrate structures, including glycoproteins and glycolipids, that constitute the glycocalyx on the luminal side of the intestinal epithelium. These molecules serve as a critical interface between the host and the external environment, playing essential roles in maintaining the mucosal barrier and facilitating communication with the gut microbiota (Nature Reviews Microbiology, 2022). They act as primary attachment sites for a wide range of pathogens, such as Vibrio cholerae, Enterotoxigenic E. coli (ETEC), and Norovirus, which utilize specialized proteins called lectins to recognize specific glycan motifs (Journal of Biological Chemistry, 2020). In clinical contexts, alterations in the glycosylation patterns of these surfaces are hallmark features of inflammatory bowel disease (IBD) and colorectal cancer, where they contribute to chronic inflammation and tumor metastasis. Therapeutic interventions targeting these glycoconjugates often involve the administration of glycomimetics, such as human milk oligosaccharides (HMOs), which act as decoy receptors to neutralize pathogens before they can bind to the host cell (Glycobiology, 2021). Additionally, probiotics and certain anti-diarrheal agents like bismuth subsalicylate interact with these surfaces to prevent bacterial adhesion and promote epithelial integrity.

Other names

Intestinal glycansMucosal glycoconjugatesGastrointestinal cell surface glycansIntestinal glycocalyxBrush border glycoconjugatesEnterocyte surface carbohydrates

Therapeutic strategies primarily utilize glycan mimetics or soluble decoy receptors to competitively inhibit the binding of pathogen-derived lectins or toxins to host cell surface glycoconjugates. Some agents also function by physically coating the epithelial surface or modulating the expression of specific glycan motifs to prevent pathogen colonization and strengthen the mucosal barrier.